Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for (CRVO)

Sponsor
Assiut University
Study ID
NCT04460001
Phase
PHASE2/PHASE3
Status
Unknown

Conditions

  • Ophthalmopathy

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Accepted

Interventions

Study Details

To compare the clinical effectiveness of ranibizumab and combination of ranibizumab and triamcinolone for the treatment of macular oedema secondary to CRVO

Key Dates

First listed
Jul 7, 2020
Start date
May 16, 2019
Status verified
Nov 2019
Primary completion
Aug 1, 2021
Completion
Dec 1, 2021

Study Design

Enrollment
100 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Ranibizumab
    intravetreal injection of Ranibizumab alone for treatment of patients with macular oedema after CRVO once per month and follow up
  • Active Comparator: Ranibizumab and triamcinolone acetate
    intravetreal injection of Ranibizumab and triamcinolone acetate for treatment of patients with macular oedema after CRVO once per month and follow up

Primary Outcome Measure

Comparison between intravitreal injection of ranibizumab and combination of ranibizumab and triamcinolone acetate for the treatment of macular edema secondary to CRVO [ Time Frame: 2 year ]

Central Contacts

Related Studies